1. Zhang X, Vadoothker S, Munir WM, Saeedi O. Ocular Surface Disease and Glaucoma Medications: A Clinical Approach. Eye Contact Lens. 2019 Jan;45(1):11-18. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298827/pdf/nihms979053.pdf 2. Uchino M, Yokoi N, Shimazaki J, Hori Y, Tsubota K, On Behalf Of The Japan Dry Eye Society. Adherence to Eye Drops Usage in Dry Eye Patients and Reasons for Non-Compliance: A Web-Based Survey. J Clin Med. 2022 Jan 12;11(2):367. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779746/pdf/jcm-11-00367.pdf. Note: this is an intersting article that discusses the poor adherence even among dry eye patients. 3. Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, de Paiva CS, Gomes JAP, Hammitt KM, Jones L, Nichols JJ, Nichols KK, Novack GD, Stapleton FJ, Willcox MDP, Wolffsohn JS, Sullivan DA. TFOS DEWS II Report Executive Summary. Ocul Surf. 2017 Oct;15(4):802-812. https://www.tearfilm.org/public/TFOSDEWSII-Executive.pdf 4. Mylla Boso AL, Gasperi E, Fernandes L, Costa VP, Alves M. Impact of Ocular Surface Disease Treatment in Patients with Glaucoma. Clin Ophthalmol. 2020 Jan 14;14:103-111. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969675/pdf/opth-14-103.pdf